Published on 18 Mar 2024 on Simply Wall St. via Yahoo Finance
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as...
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term Hikma Pharmaceuticals PLC (LON:HIK) shareholders, since the share price is down 18% in the last three years, falling well short of the market return of around 16%.
Since Hikma Pharmaceuticals has shed UK£140m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.
View our latest analysis for Hikma Pharmaceuticals